PTU - Polskie Towarzystwo Urologiczne
list of articles:

Radiotherapy as one of the treatment modality of localized prostate cancer
Article published in Urologia Polska 2001/54/4.


Piotr Milecki 1, Grażyna Stryczyńska 1, Tomasz Stachowski 2, Zbigniew Kwias 2
1 Zakład Radioterapii, Wielkopolskie Centrum Onkologii. Poznań Kierownik zakładu: dr n. med. Grażyna Stryczyńska
2 Katedra i Klinika Urologii AM im. K. Marcinkowskiego w Poznaniu Kierownik katedry: prof, dr med. Zbigniew Kwias


prostate cancer, three dimensional conformal radiotherapy, combined treatment


The high-dose 3D conformal radiotherapy as one of treatment mode in the localised prostate cancer has been presented, as the generally accepted treatment strategy in this stage of disease has not been established yet. The technological advance in the quality of irradiation (alculating and delivery of dose in the target and organ at risks) thai could be observed in the last few years together with introducing of a new 3D conformal radiation therapy may lead to significant the therapeutic gain. The outcomes of treatment of the prostate cancer in early stage of disease (1-2 NO MO) by applicating the high-dose three dimensional radiotherapy (D CRT) alone are comparable to radical prostatectomy. In the group of patients who refused surgery, radiotherapy is only radical mode of treatment. In advanced stage of disease (T3-4 NO VI 0) combined radiotherapy with hormonotherapy may increase the survival of patients. The postoperative radiotherapy in the group of patients with high risk of local recurrence (pT2/3 NO M 0) also improves outcomes of treatment.


  1. 1. Zatoński SN\\\'. Nowotwory złośliwe w Polsce. Cenlrum Onkologii, Warszawa 1993.
  2. 2. Cocbcrgh JW, Sant M, Bcrino F: Survival of adult cancer patients in Europe diagnosed from 1978-1989: The Eurocarc II study. EJC 1998, 34, 14.
  3. 3. The American Urological Association Prostate Cancer Clinical guidelines panel. Baltimore: American Urological Association, 1995.
  4. 4. Zagars GK, Pollack A, von Eschenbach AC. Managment of unfavorable locoregional prostate carcinoma with radiation and androgen ablation. Cancer 1997,15, 764-75.
  5. 5. Roach M, Pickett B, Phillips TL. The advantages and limitation of tlnee-dimensionalfy (3D) based coplanar external beam irradiation (XRT) in the treatment of localized prostate cancer. In European Association of Radiolog)\\\' Workshop, Chicago, Oct. 19-20, 1993.
  6. 6. Zelcfsky MJ, Cowcn D, Fuks Z, Shike M, Burman C, Jacson A, Venkatramen ES, Lcibel SA. Long term tolerance of high dose three-dimensional confoimal radiotherapy in patients with localized prostate carcinoma. 1999, 1, 246(1—8.
  7. 7. Pickett B, Vigneault E, Kurhanewicz J, Vehey L, Roach M. Static field intensity modulation to treat a dominant inira-prostalic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. Int I Radial Oncol Biol Phys. 1999, 1, 921- 9.
  8. 8. Pollack A, Zagars GK. External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys, 1997, 39, 1011-1018.
  9. 9. Hanks GE, Ilanlon AL, Pinover WH, Horowitz E M, Schulthe-siss TE. Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy. Cancer J Sci Am 1999, 5,152-8.
  10. 10. Lamer J, Spencer G, Grizos W. Significance of CT scan detected seminal vesicle enlargment in prostate cancer: a pilot study. Urology 1993,41:259.
  11. 11. Effert P, Boeckmann W, Wolff J, Jakse G: Laparoscopic lym-phadenectomy in prostate carcinoma. Experiences with 120 patients. Urologca 1996, 35, 413-7.
  12. 12. Stone NN, Stock RG: Laparoscopic pelvic lymph node dissection in the staging of prostate cancer. Mt sinai I Med. 1999, 66, 26-30.
  13. 13. Stock RG, Stone NN, Ianuzzi C, Unger P: Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection: implications for patient selection in the radiotherapeutic management of prostate cancer. Int J Radiat Oncol Biol Phys 1995, 33, 815-21.
  14. 14. Asbell SO, Krall JM, Pilepich MV i wsp. Elective pelvic iiradia-tion in stage A2, B carcinoma of prostate: analysis ofRTOG 77-06. Int J Radiat Oncol Biol Phys 1988,15,1307.
  15. 15. Stock RG, Ferrari AC Stone NN: Dose pelvic irradiation play a role in the managment of prostate cancer? Oncology 1998, 12, 1475-76.
  16. 16. Gerber GS, Bales GT, Górnik HL, Haraf DJ, Chodak GW, Rukstalis DB. Treatment of prostate cancer using external beam radiotherapy after laparoscopic pelvic lymph node dissection. Br J Urol 1996, 77, 870-5.
  17. 17. Schikl SE, Buskirk SJ, Wong WW, Halyard MY, Swanson SK, Nowicki DE, Ferringi RG. The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. J Urol 1996, 156,1725-9.
  18. 18. Petrovich Z, Lieskovsky G, Langholz B, Formenti S, Baert L, Streeter O, Skinner D. G. Radical prostatectomy and postoperative irradiation in patients with pathological stage C (3) carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1998,1,139-47.
  19. 19. Mazcron JJ, Bolla M. Localized prostatic adenocarcinoma: role of pelvic radiotherapy following radical prostatectomy. Cancer Radiolher 1997, 1, 423-30.
  20. 20. Eulau SM, Tate DJ, Stamey TA, i wsp. Effect of combined transient androgen deprivation and inadiation following radical prostatectomy for prostatic cancer. Int J Radiat Oncol Biol Phys 1998,41,735-740.
  21. 21. Laverdiere J, Gomez JL, Cusan L. i wsp. Beneficial effect of combination therapy administered prior to and following external beam radiation therapy in localized prostate cancer, Jnl J Radiat Oncol Biol Phys 1997, 37, 247.
  22. 22. Bolla M., Gonzalez D, Warde P, i wsp. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and gosorelin. N Engl J Med 1997, 337: 295-300.
  23. 23. Pilepich MV, Sause WT, Shipley WU, i wsp. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Croup. Urology 1995, 45, 616-623.
  24. 24. Zagars GK, Pollack A, Smith LG. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage 111 (T3, NxtNO, M0) adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1999,1, 809-19. 24. 25.
  25. 25. Critz FA, Lcvinson AK, Williams WH, Holladay DA. Prostate specific antigen nadir: the optimum level after irradiation for prostate cancer. J Clin Oncol 1996, 14, 2893-900.
  26. 26. Conell PP, Ignacio L, McBride RB, Weichselbaum RR, Vijay-akumar S. Caution in inteipreting biochemical control rates after treatment of prostate cancer: Leght of follow-up influences results. Urology 1999, 54, 875.
  27. 27. Cheng L, Cheville JC, Bostwick DG. Diagnosis of prostate cancer in needle biopsies after radiation therapy. Am J Surg Pathol 1999,23,1173-83.


Piotr Mitecki
Wielkopolskie Centrum Onkologii Zakład Radioterapii
ul Garbaty 15
tel. 8540-535, 8540-536, kom. 0607-638-442, e-mail: pmileck@wco.pi